DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2017年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3429

Title: Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.
Other Titles: 肝線維化におけるペリオスチンの役割 : レニン・アンギオテンシン系とクロストーク
Authors: Takeda, Kosuke
Noguchi, Ryuichi
Kitade, Mitsuteru
Namisaki, Tadashi
Moriya, Kei
Kawaratani, Hideto
Okura, Yasushi
Kaji, Kosuke
Aihara, Yosuke
Douhara, Akitoshi
Nishimura, Norihisa
Sawada, Yasuhiko
Seki, Kenichiro
Yoshiji, Hitoshi
Keywords: periostin
angiotensin II
liver fibrosis
renin-angiotensin system
choline-supplemented amino acid
Issue Date: Nov-2017
Publisher: Spandidos Publications
Citation: Molecular medicine reports Vol.16 No.5 p.5752-5758 (2017 Nov)
Abstract: Periostin is a 90‑kDa extracellular matrix protein, which is secreted primarily from fibroblasts and is expressed in the lungs, kidneys and heart valves. Angiotensin II (AT‑II) serves pivotal roles in the pathogenesis of several diseases with accompanying fibrosis, including chronic liver diseases. AT‑II induces periostin expression by regulating transforming growth factor‑β1 (TGF‑β1)/Smad signaling during cardiac fibrosis. The aim of the present study was to investigate the interaction between AT‑II and periostin during liver fibrosis development. Fischer 344 rats were fed a choline‑deficient L‑amino‑acid (CDAA)‑defined diet for 12 weeks to simulate the development of steatohepatitis with liver fibrosis. Losartan, an AT‑II type I receptor blocker, was administered to inhibit the effect of AT‑II. The therapeutic effect of losartan on hepatic fibrosis development and on periostin expression was then evaluated. Several in vitro experiments were performed to examine the mechanisms underlying the interaction between AT‑II and periostin in activated hepatic stellate cells (Ac‑HSCs). Treatment with losartan suppressed the development of liver fibrosis induced by the CDAA diet, and reduced hepatic periostin expression. In addition, losartan treatment suppressed hepatic Ac‑HSC expansion and hepatic TGF‑β1 expression. In vitro analysis using LX2 HSC cells indicated that AT‑II can augment TGF‑β1 and collagen type I α1 mRNA expression via periostin expression, suggesting that the interaction between AT‑II and periostin may serve a role in liver fibrosis development. In conclusion, blockade of AT‑II‑induced periostin may suppress the progression of liver fibrosis development.
Description: 博士(医学)・乙第1413号・平成30年3月15日
Copyright: © Takeda et al. This is an open access article distributed under the terms of Creative Commons Attribution License(CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/.
URI: http://hdl.handle.net/10564/3429
ISSN: 17912997
Academic Degrees and number: 24601B1413
Degree-granting date: 2018-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2017年度

Files in This Item:

File Description SizeFormat
01乙1413本文の要旨.pdf乙1413本文の要旨1.83 MBAdobe PDFView/Open
02乙1413審査要旨.pdf乙1413審査要旨581.14 kBAdobe PDFView/Open
03乙1413本文.pdf乙1413本文1.18 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback